Attributes | Values |
---|
rdf:type
| |
description
| - clinical trial (en)
- ensayu clínicu (ast)
- klinisch onderzoek (nl)
- клінічне випробування (uk)
|
rdfs:label
| - Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 o (en)
- Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 o (nl)
|
skos:prefLabel
| - Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 o (en)
- Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 o (nl)
|
name
| - Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 o (en)
- Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 o (nl)
|
title
| |
title
| - A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis (en)
|
end time
| |
end time
| |
instance of
| |
instance of
| |
start time
| |
start time
| |
country
| |
country
| |
research site
| |
research site
| |
short name
| |
short name
| |
minimum age
| |
minimum age
| |
medical condition
| |
medical condition
| |
number of participants
| |
number of participants
| |
study type
| |
study type
| |
ClinicalTrials.gov ID
| |
ClinicalTrials.gov ID
| |
clinical trial phase
| |
clinical trial phase
| |
is about
of | |